Tonix Pharmaceuticals' TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has published preclinical data in Cancer Cells demonstrating the efficacy of its fusion protein candidate, mTNX-1700, in enhancing immunotherapy for gastric cancer. The study, conducted in collaboration with Columbia University Medical School, found that mTNX-1700 significantly increased survival rates and reduced metastases in mouse models by depleting immunosuppressive neutrophils and inhibiting cancer-driven granulopoiesis. This breakthrough supports the development of TNX-1700, the human version of the protein, as a potential treatment for gastric and colorectal cancers, offering hope for overcoming checkpoint resistance in solid tumors.

The findings underscore the importance of TNX-1700 in the broader context of cancer treatment, particularly for patients who do not respond to current immunotherapy options. Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, emphasized the significance of these results for advancing the company's pipeline of immunotherapy resistance solutions. With TNX-1700 in development, Tonix Pharmaceuticals is at the forefront of addressing one of the most challenging aspects of cancer treatment, potentially improving outcomes for patients with limited options.

For further details on the study and Tonix Pharmaceuticals' innovative approach to cancer treatment, visit https://ibn.fm/PPxKC.